QTTB compared with PRLD: revenue, margins and what each company keeps, and the suppliers and customers both name

QTTBQ32 Bio Inc.

Mkt capRevenueRevenue

PRLDPrelude Therapeutics Inc

Mkt capRevenueRevenue

Compare

QTTBQ32 Bio Inc.

PRLDPrelude Therapeutics Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

QTTB1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±16.2%▲+2.07%×0.13

PRLD1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.9%▲+10.14%×0.56

= impliedQTTB realized, solidPRLD realized, hatchedOne scale, both sides: full bar = 18%× = |realized| ÷ impliedSource: market data

QTTBQ32 Bio Inc.

8.79▲+0.95%

Mkt cap$259.3MRevenue$54MQ4 FY25

PRLDPrelude Therapeutics Inc

3.77▼−1.72%

Regular sessionNov 3 '26

Mkt cap$306.4MRevenue$6MQ2 FY26

Compare

Regular sessionNov 3 '26

QTTBQ32 Bio Inc.

PRLDPrelude Therapeutics Inc

8.79▲+0.95%

Price

3.77▼−1.72%

$259.3M

Mkt cap

$306.4M

Q4 FY25$54M

Revenue

$6MQ2 FY26

QTTB8.79▲+0.95%vsPRLD3.77▼−1.72%Regular sessionNov 3 '26